Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
COLORADO SPRINGS, Colo., April 07, 2016 -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release first quarter 2016 financial results after the market close on Thursday, April 28, 2016. Company management will host a conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, April 28, 2016 to discuss results and provide a general business update.
The dial-in for the conference call is (877) 561-2747 for domestic callers or (973) 409-9689 for international callers. The Conference ID is 81186531. There will also be a live webcast of the call on the investor relations section of the Company’s website at www.spectranetics.com. The webcast will be available on the Company’s website for 14 days following the completion of the call.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt® scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads. For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen [email protected] (719) 447-2292 Michaella Gallina [email protected] (719) 246-1713
